BioCentury
ARTICLE | Clinical News

Diazoxide choline controlled release: Phase I started

July 14, 2014 7:00 AM UTC

Essentialis began the 2-part, U.S. Phase I PC025 trial of oral DCCR in 12 obese Prader-Willi patients ages 10-20 years. In the open-label first part, patients will receive a starting dose of 1.5 mg/kg...